- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05390294
Survival With Patients Treated With Salivary Gland Cancer
May 22, 2022 updated by: Denis Brajković, Clinical Center of Vojvodina
Prognostic Factors for Survival of Patients With Salivary Gland Malignancies
Salivary gland malignancies is very heterogenous group of tumors regarding tumor histology and localization.
The aim of this study is to assess main clinical and pathological parameters related to patients survival
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The retrospective study enrolled medical charts of the patients treated due to salivaly gland cancers in the Clinic for maxillofacial surgery at Clinical center of Vojvodina in the period of 1. January 1996.
to 31.
December 2021.
Patients demographics, type of the tumor, localization, TNM status and patohystological parameters were evaluated for patients survival and disease free periods
Study Type
Observational
Enrollment (Actual)
250
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Novi Sad, Serbia, 11000
- Clinic for maxillofacial surgery Clinical center of Vojvodina
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients treated due to SGC in the Clinic for maxillofacial surgery at Clinical center of Vojvodina
Description
Inclusion Criteria:
Patients with salivary gland malignancies treted in the Clinic for maxillofacial surgery
Exclusion Criteria:
Incomplete medical data Patients with metastatic tumord of salivary gland Patients with recurrent malignancies of salivary glands sent from other clinics
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Patients free of the disease
Patients treated due to SGC without local recurrence or metastases
|
Surgical intervention with or without postoperative adjuvant therapy
|
|
Patients with the disease
Patient with relapse of SGC, metastases or died due to SGC
|
Surgical intervention with or without postoperative adjuvant therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Patients survival
Time Frame: Through study completion, an average of 1 year
|
Survival of patients treated due to SGC during observation period of minimum 2 years
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2022
Primary Completion (Actual)
March 30, 2022
Study Completion (Actual)
April 30, 2022
Study Registration Dates
First Submitted
May 18, 2022
First Submitted That Met QC Criteria
May 22, 2022
First Posted (Actual)
May 25, 2022
Study Record Updates
Last Update Posted (Actual)
May 25, 2022
Last Update Submitted That Met QC Criteria
May 22, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1106012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Salivary Gland Neoplasms
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Salivary Gland Carcinoma | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland Carcinoma | Locally Advanced Salivary Gland CarcinomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedRecurrent Salivary Gland Cancer | Stage IVA Salivary Gland Cancer | Stage IVB Salivary Gland Cancer | Stage IVC Salivary Gland CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingRecurrent Salivary Gland Carcinoma | Stage III Major Salivary Gland Cancer AJCC v8 | Stage IV Major Salivary Gland Cancer AJCC v8 | Metastatic Salivary Gland Carcinoma | Unresectable Salivary Gland CarcinomaUnited States
-
University of Erlangen-Nürnberg Medical SchoolRecruitingSalivary Gland Tumor | Benign Salivary Gland TumorGermany
-
Northwestern UniversityBristol-Myers Squibb; National Cancer Institute (NCI)Active, not recruitingMajor Salivary Gland Carcinoma | Recurrent Salivary Gland Carcinoma | Stage IVA Major Salivary Gland Carcinoma | Stage IVB Major Salivary Gland Carcinoma | Stage IVC Major Salivary Gland Carcinoma | Minor Salivary Gland Carcinoma | Stage IV Major Salivary Gland CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Salivary Gland Cancer | Stage IVA Salivary Gland Cancer | Stage IVB Salivary Gland Cancer | Stage IVC Salivary Gland Cancer | High-grade Salivary Gland Mucoepidermoid Carcinoma | Salivary Gland Acinic Cell Tumor | Salivary Gland Adenocarcinoma | Salivary Gland Poorly Differentiated CarcinomaUnited States
-
Peking Union Medical CollegeNot yet recruiting
-
Cairo UniversityUnknownMalignant Neoplasm of Salivary Gland | Benign Neoplasm of Salivary GlandEgypt
-
King Faisal Specialist Hospital & Research CenterRadiation Therapy Oncology GroupCompletedMalignant Salivary Gland TumorsSaudi Arabia
-
Abramson Cancer Center at Penn MedicineMcCabe FundRecruiting
Clinical Trials on Surgical intervention with or without postoperative adjuvant therapy
-
Lei LiRecruitingRecurrence | Survival Outcomes | Adjuvant Therapy | Hormone Therapy | Low Grade Endometrial Stromal Sarcoma of Uterus (Diagnosis) | Fertility-sparing Surgery | Fertility OutcomesChina
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Amsterdam UMCRecruiting
-
Insel Gruppe AG, University Hospital BernRecruitingAortic Valve Replacement in Patients With Moderate Aortic Stenosis Combined With Mitral RegurgitationSwitzerland
-
Papa Giovanni XXIII HospitalNot yet recruitingPercutaneous Coronary Intervention | Coronary Artery Disease (CAD) | Intravascular Lithotripsy; Rotational Atherectomy; OFDI | Optical Coherence Tomography (OCT) | Calcific Coronary Arteriosclerosis | Intravascular Ultrasound | Orbital AtherectomyItaly
-
Pusan National University HospitalUnknownLung Cancer | Surgery | Effects of Chemotherapy | Cancer of Lymph NodeKorea, Republic of
-
Alice ChungRecruitingBreast Cancer | Mastectomy; Lymphedema | Female Breast Cancer | Axilla; Breast | Tumor, Breast | Axillary Nodal DiseaseUnited States
-
Greenwich HospitalYale UniversityCompletedCervical Spondylotic MyelopathyUnited States
-
Population Health Research InstituteCompletedST Elevation Myocardial Infarction | Acute Coronary Syndrome | Percutaneous Coronary InterventionCanada, United States, Korea, Republic of, United Kingdom, Spain, New Zealand, France, Greece, Austria, Netherlands, Germany, Finland, Serbia, Czech Republic, Australia, Hungary, Brazil, Belgium, China, Macedonia, The Former Yugoslav...
-
DynPort Vaccine Company LLC, A GDIT CompanyCompleted